Gwella

Gwella Goes International with Stronger Microdose Gummies in 2022

Consumer Product of the Year Winner Announces Global Extra-Strength Option for Microdosing


In mid-October 2022, Gwella, a direct-to-consumer functional mushroom brand, is excited to announce the launch of its newest mushroom gummy. Mojo Microdose Gummies – Mojo Macro is an extra-strength version of the brand’s already popular regular-strength Mojo gummies. Gwella’s Mojo gummies offer a legal option for people to experience the benefits of microdosing: focus, energy, mental clarity, and feelings of positivity.

Growing Popularity

Touted as the world’s first legal microdose alternative, Gwella’s non-hallucinogenic gummies, Mojo Microdose gummies, quickly sold out during their 2021 release. In addition to receiving some excellent consumer reviews, Mojo also won Consumer Product of the Year during the 1st Annual Microdose Awards.

After a successful initial run, Gwella ramped up the production of its flagship product to meet a growing consumer base. In response to widespread international interest, the regular- and extra-strength Mojo gummies can now be shipped to customers worldwide, including the UK where consumer demand has been extremely high. Aside from a few countries with stricter restrictions on functional mushrooms, Mojo products are 100% legal.

Functional Ingredients

Mojo gummies are engineered with a stack of unique bioactives to stimulate the reported pharmacological benefits of microdosing psilocybin, without any of the legal worries.

Mojo uses proprietary Cordyceps that helps naturally boost mood, while the nootropics combined with Lion’s Mane help enhance focus and improve mental clarity. After taking Mojo gummies regularly, some users can decrease their daily caffeine intake without affecting their energy levels. The addition of ginseng and slow-releasing caffeine provide a non-jittery brain boost and a reduction in brain fog.

Microdosing magic mushrooms allow people to feel creative, clear-headed, and present. Gwella’s Mojo gummies help people explore the psychedelic world without the illegal components. According to Daniel Sanders, Gwella’s Chief Science Officer, Mojo’s “non-hallucinogenic, non-psychedelic formula leverages the adaptogenic and functional benefits of mushrooms to improve individual baselines across their health and productivity.”

The synergy of the active ingredients working together make the Mojo formula both safe and effective.

Short and Long-Term Benefits

As health and wellness continue to trend in a post-pandemic world, Mojo gummies serve as a legal microdose alternative that affords immediate and long-term wellness advantages. Gwella recommends taking no more than six gummies in a 12-hour period and alternating five days on and two days off if you plan on starting a routine.

In as little as a half-hour, users can experience a clean and consistent energy boost that mimics the flow state associated with microdosing for 5+ hours! For some, taking one Mojo gummy can increase focus, mental clarity, and calmness after the release period. Others may need to take more than one to experience their next level focus.

Long-term benefits, like improved mood and brain cognition, can occur when you take the gummies as part of a routine. Although Gwella doesn’t make medical claims since they haven’t conducted clinical trials yet, consumers have reported that taking Mojo gummies helps them get a midday pick-me-up, achieve better sleep and generally attain an improved mental state.

The Conversation (0)

Compass Pathways to participate in three investor conferences in September

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in the following September investor conferences:

  • Morgan Stanley 22nd Annual Global Healthcare Conference: fireside chat at 7:45 am ET on September 4, 2024, and host investor meetings
  • H. C. Wainwright 26th Annual Global Investment Conference: fireside chat at 9:30 am ET on September 10, 2024, and host investor meetings
  • Cantor Global Healthcare Conference: fireside chat at 2:30 pm ET on September 17, 2024, and host investor meetings

A live audio webcast of these events will be accessible from the "Events" page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

COMPASS Pathways to participate in Canaccord Genuity 44th Annual Growth Conference

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in the Canaccord Genuity 44th Annual Growth Conference: presentation at 4:30pm ET on August 13, 2024 and host investor meetings.

A live audio webcast of this event will be accessible from the "Events" page of the Investors section of the Compass website. A replay of this webcast will be accessible for 30 days following such event. For more information, please visit investor section of compasspathways.com.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Psychedelic mushrooms.

Psychedelics Market Update: H1 2024 in Review

The global psychedelics market will likely experience continued growth and interest in the coming years.

According to findings from FactMR, the sector's value is projected to surpass US$603.1 million in 2024, with further growth expected at a CAGR of 7 percent. By 2034, the psychedelics industry is projected to be worth US$1.18 billion.

The field of psychedelics-based therapies has shown significant growth in the past few years as medical companies focus on developing alternative treatments for various mental health conditions, including depression, post-traumatic stress disorder (PTSD), major depressive disorder (MDD), generalized anxiety disorder (GAD), addiction and other ailments.

Keep reading...Show less
Melodiol Global Health

Quarterly Activities Report: Melodiol Delivers $9.3m in Revenue During H1 FY24 – a 33% Increase the PCP

Melodiol Global Health Limited (ASX:ME1) (‘Melodiol’ or ‘the Company’) is pleased to provide the following update on progress for the three month period ended 30 June 2024 (the ‘quarter’), as well as its Appendix 4C. All financial results are in Australian dollars and unaudited (unless otherwise stated).

Keep reading...Show less
Melodiol Global Health Limited

Corporate Update

Melodiol Global Health Limited (ASX:ME1) (‘Melodiol’ or ‘the Company’) is pleased to advise that it has raised $1.1m in new capital in the form of an equity placement and a loan.

Keep reading...Show less
Melodiol Global Health Limited

Melodiol Global Health Limited (ASX: ME1) – Trading Halt

Description

The securities of Melodiol Global Health Limited (‘ME1’) will be placed in trading halt at the request of ME1, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Tuesday, 30 July 2024 or when the announcement is released to the market.

Keep reading...Show less

Latest Press Releases

Related News

×